Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 7/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20325460 | 0.98 | PARP10 (0.55) | PARP15PARP10PARP2MMP3GRM2 | |
| SCHEMBL18088475 | 0.93 | PARP15 (0.51) | PARP15PARP10PARP2ALDH1A1LMNA | |
| SCHEMBL3548626 | 0.93 | PARP15 (0.51) | PARP15PARP10PARP2ALDH1A1LMNA | |
| SCHEMBL29660023 | 0.86 | RORC (0.51) | PARP15PARP10PARP2GRM2ALDH1A1 | |
| SCHEMBL6967590 | 0.84 | NFE2L2 (0.58) | GRM2HPGDALDH1A1LMNAGAA | |
| SCHEMBL21035567 | 0.83 | PARP15 (0.43) | PARP15PARP10PARP2MMP3ALDH1A1 | |
| SCHEMBL21501125 | 0.83 | NFE2L2 (0.60) | GRM2HPGDALDH1A1LMNAGAA | |
| SCHEMBL20303849 | 0.82 | PARP15 (0.59) | PARP15PARP10PARP2MMP3 | |
| SCHEMBL21035101 | 0.80 | PARP10 (0.47) | PARP15PARP10PARP2GRM2HPGD | |
| SCHEMBL31195140 | 0.78 | PARP15 (0.46) | PARP15PARP10PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322676-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARM INC (US) | 2019-10-24 | — | — | US | disclosed |
| WO-2018118838-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322676-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | UGCG, MAN2B1, GBA1 | PARP15 851/4885PARP10 688/4885PARP2 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.